Bull vs Bear: GlaxoSmithKline

GlaxoSmithKline (GSK) is a company that divides opinion and therefore an ideal candidate for the IC's Bull vs Bear series. In this episode, Simon Gergel from the Merchants Trust argues the bull case against the ICs pharma specialist (and GSK sceptic), Megan Boxall.Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities. Investors' Chronicle is a service by the Financial Times. Hosted on Acast. See acast.com/privacy for more information.

Episode metadata supplied by the publisher feed · Published May 16, 2018

Embed this episode

Attribution link and audio player

NOW PLAYING

Bull vs Bear: GlaxoSmithKline

0:00 18:33

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Investors' Chronicle?

This episode is 18 minutes long.

When was this Investors' Chronicle episode published?

This episode was published on May 16, 2018.

Can I download this Investors' Chronicle episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!